Brain-derived EVs are able to cross the blood-brain barrier,
protecting their payload from enzymatic degradation, and are easily recovered from biofluids. Interestingly, EV
content is strongly influenced by the specific pathophysiological status of the donor cell. In this manuscript, the
role of EVs as source of novel PD biomarkers is discussed, providing all recent findings concerning relevant
proteins and miRNAs carried by PD patient-derived EVs, from several biological specimens. Moreover, the
contribution of mitochondria-derived EVs will be dissected. Finally, the promising possibility to use EVs as source
of markers to monitor PD therapy efficacy will be also examined. In the future, larger cohort studies will help to
validate these EV-associated candidates, that might be effectively used as non-invasive and robust source of
biomarkers for PD. CLICK TO REVIEW